UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Grows Stock Position in 10x Genomics $TXG

Key Points

• UBS Asset Management raised its stake in 10x Genomics by 235.6% in Q1, owning 5.81% of the company with holdings worth $62 million after acquiring nearly 5 million shares.
• The company reported $0.28 earnings per share, significantly beating analysts' expectations of a loss, and its revenue increased by 12.9% year-over-year to $172.91 million.
• Institutional investors hold 84.68% of 10x Genomics' stock, indicating strong confidence in the company, though recent analyst ratings vary from "buy" to "sell."

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in 10x Genomics (NASDAQ:TXG - Free Report) by 235.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 7,103,768 shares of the company's stock after buying an additional 4,987,195 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 5.81% of 10x Genomics worth $62,016,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in TXG. Cetera Investment Advisers lifted its stake in shares of 10x Genomics by 22.7% in the 4th quarter. Cetera Investment Advisers now owns 19,898 shares of the company's stock valued at $286,000 after purchasing an additional 3,679 shares during the period. Deutsche Bank AG increased its holdings in shares of 10x Genomics by 35.3% during the fourth quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock valued at $146,000 after acquiring an additional 2,657 shares in the last quarter. Gotham Asset Management LLC bought a new position in shares of 10x Genomics during the fourth quarter valued at $264,000. Jacobs Levy Equity Management Inc. bought a new position in shares of 10x Genomics during the fourth quarter valued at $450,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of 10x Genomics by 37.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,165 shares of the company's stock valued at $2,286,000 after acquiring an additional 42,950 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

Analyst Ratings Changes

TXG has been the subject of several analyst reports. Bank of America raised their price target on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Thursday, June 26th. Wall Street Zen lowered 10x Genomics from a "buy" rating to a "hold" rating in a report on Saturday, September 13th. Zacks Research lowered 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Friday, September 5th. Barclays reissued an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Finally, Piper Sandler started coverage on 10x Genomics in a report on Thursday, September 11th. They issued a "neutral" rating and a $15.00 target price for the company. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $13.65.

Insider Transactions at 10x Genomics

In other news, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the transaction, the chief executive officer directly owned 945,892 shares of the company's stock, valued at approximately $13,043,850.68. The trade was a 0.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Adam Taich sold 22,315 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. This represents a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 39,149 shares of company stock valued at $539,865. Corporate insiders own 9.39% of the company's stock.

10x Genomics Price Performance

Shares of NASDAQ:TXG traded down $0.23 during trading on Friday, hitting $13.04. 3,262,793 shares of the company's stock were exchanged, compared to its average volume of 2,167,720. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $23.53. The business's 50-day simple moving average is $13.29 and its 200 day simple moving average is $10.90. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -18.63 and a beta of 2.00.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm had revenue of $172.91 million during the quarter, compared to analysts' expectations of $139.36 million. During the same quarter in the previous year, the business earned ($0.32) EPS. The company's quarterly revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. On average, sell-side analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.